Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Core Insights - Acrivon Therapeutics is advancing ACR-2316, a selective dual WEE1 and PKMYT1 inhibitor, demonstrating strong preclinical activity and designed for superior single-agent efficacy [1][2] - The company utilizes its proprietary AP3 platform to identify patient responders and mechanisms of drug resistance, enhancing the potential for effective cancer treatments [6] Group 1: Product Development - ACR-2316 is the first fully internally-discovered candidate from Acrivon, generated through co-crystallography-based drug design, aimed at addressing limitations of existing WEE1 and PKMYT1 inhibitors [2] - Acrivon is also advancing ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial with Fast Track designation from the FDA for specific cancer types [6] Group 2: Research Presentation - Acrivon will present data at the AACR Annual Meeting from April 5-10, 2024, showcasing the potential of ACR-2316 and insights from the AP3 platform regarding resistance mechanisms to ACR-368 [1][3] - The presentations will include a poster on ACR-2316's design and efficacy, as well as findings on overcoming resistance to ACR-368 through combination treatments [3][4]